z-logo
Premium
New malignancies following cancer of the urinary bladder: analysis of German cancer registry data
Author(s) -
LEHNERT M.,
KRAYWINKEL K.,
PESCH B.,
HOLLECZEK B.,
BRÜNING T.
Publication year - 2012
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/j.1365-2354.2011.01315.x
Subject(s) - medicine , bladder cancer , cancer registry , cancer , renal pelvis , prostate cancer , confidence interval , incidence (geometry) , population , gynecology , urinary system , urology , oncology , environmental health , physics , optics
LEHNERT M., KRAYWINKEL K., PESCH B., HOLLECZEK B. & BRÜNING T. (2012) European Journal of Cancer Care 21 , 398–402 New malignancies following cancer of the urinary bladder: analysis of German cancer registry data This analysis aimed at occurrence and distribution patterns of new malignancies following bladder cancer. Standardised incidence ratios (SIRs) were calculated for two German population‐based cancer registries of North Rhine‐Westphalia (NRW) and Saarland to access risks for subsequent primaries. An elevated risk for secondary cancer of any site but urothelium was observed in NRW men [SIR 1.35, 95% confidence interval (CI) 1.22–1.49]. The corresponding risk in Saarland was not significantly elevated (SIR 1.06, 95% CI 0.97–1.15). In data of both registries excess risks were observed for cancer of the respiratory tract (SIR 1.54, CI 1.23–1.89 in NRW men) and the prostate (SIR 1.91, 95% CI 1.61–2.24 in NRW; SIR 1.25, 95% CI 1.07–1.45 in Saarland). Common risk factors and incidental findings during follow‐up care of bladder cancer patients might explain most of the observed patterns. In addition SIRs were throughout particular high for subsequent cancer of the renal pelvis and the ureter due to pathological characteristics of urothelial neoplasms.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here